UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

November 30, 2027

Conditions

Myasthenia Gravis

Interventions

BIOLOGICAL

UCAR T-cell group

A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells

Trial Locations (1)

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors

collaborator

Shanghai Xiniao Biotech Co., Ltd.

INDUSTRY

lead

Zhejiang University

OTHER